Articles dans des revues avec comité de lecture (169)
  1. 20. Soumoy, L., Schepkens, C., Krayem, M., Najem, A., Tagliatti, V., Ghanem, G. E., Saussez, S., Colet, J.-M., & Journé, F. (2020). Metabolic reprogramming in metastatic melanoma with acquired resistance to targeted therapies: Integrative metabolomic and proteomic analysis. Cancers (Basel), 12(5), 1323. doi:10.3390/cancers12051323
  2. 21. Krayem, M., Aftimos, P., Najem, A., van den Hooven, T., van den Berg, A., Hovestad-Bijl, L., de Wijn, R., Hilhorst, R., Ruijtenbeek, R., Sabbah, M., Kerger, J., Awada, A., Journé, F., & Ghanem, G. E. (2020). Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma. Cancers (Basel), 12(2). doi:10.3390/cancers12020512
  3. 22. Krayem, M., Sabbah, M., Najem, A., Wouters, A., Lardon, F., Simon, S., Sales, F., Journé, F., Awada, A., Ghanem, G. E., & Van Gestel, D. (2019). The benefit of reactivating p53 under MAPK inhibition on the efficacy of radiotherapy in melanoma. Cancers (Basel), 11(8), 1093. doi:10.3390/cancers11081093
  4. 23. Soumoy, L., Kindt, N., Ghanem, G. E., Saussez, S., & Journé, F. (2019). Role of macrophage migration inhibitory factor (Mif) in melanoma. Cancers (Basel), 11(4), 529. doi:10.3390/cancers11040529
  5. 24. Krayem, M., Najem, A., Journé, F., Morandini, R., Sales, F., Awada, A., & Ghanem, G. E. (2018). Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma. Oncotarget, 9(61), 31888-31903. doi:10.18632/oncotarget.25879
  6. 25. Perdrix, A., Najem, A., Saussez, S., Awada, A., Journé, F., Ghanem, G. E., & Krayem, M. (2017). PRIMA-1 and PRIMA-1Met (APR-246): From mutant/wild type p53 reactivation to unexpected mechanisms underlying their potent anti-tumor effect in combinatorial therapies. Cancers (Basel), 9(12), 172. doi:10.3390/cancers9120172
  7. 26. Kindt, N., Journé, F., Ghanem, G. E., & Saussez, S. (2017). Galectins and carcinogenesis: Their role in head and neck carcinomas and thyroid carcinomas. International journal of molecular sciences, 18(12), 2745. doi:10.3390/ijms18122745
  8. 27. Najem, A., Krayem, M., Perdrix, A., Kerger, J., Awada, A., Journé, F., & Ghanem, G. E. (2017). New drug combination strategies in melanoma: Current status and future directions. Anticancer research, 37(11), 5941-5953. doi:10.21873/anticanres.12041
  9. 28. Gilot, D., Migault, M., Bachelot, L., Journé, F., Rogiers, A., Donnou-Fournet, E., Mogha, A., Mouchet, N., Pinel-Marie, M. L., Mari, B., Montier, T., Correia, S., Gautron, A., Rambow, F., El Hajj, P., Ben Jouira, R., Tartare-Deckert, S., Marine, J.-C., Felden, B., Ghanem, G. E., & Galibert, M. D. (2017). A non-coding function of TYRP1 mRNA promotes melanoma growth. Nature cell biology, 19(11), 1348-1357. doi:10.1038/ncb3623
  10. 29. Zhang, Y., Guo, J., Yang, W., Goncalves, C., Rzymski, T., Dreas, A., Zyłkiewicz, E., Mikulski, M., Brzózka, K., Golas, A., Kong, Y., Ma, M., Huang, F., Huor, B., Guo, Q., Da Silva, S. D., Rivera-Torres, J., Cai, Y., Topisirovic, I., Su, J., Bijian, K., Alaoui-Jamali, M. A., Huang, S., Journé, F., Ghanem, G. E., Miller, W. W., & Del Rincón, S. S. (2017). MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma. The Journal of clinical investigation, 127(11), 4179-4192. doi:10.1172/JCI91258
  11. 30. Najem, A., Krayem, M., Sales, F., Hussein, N., Badran, B., Robert, C., Awada, A., Journé, F., & Ghanem, G. E. (2017). P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. European journal of cancer, 83, 154-165. doi:10.1016/j.ejca.2017.06.033
  12. 31. Wimana, Z., Ghanem, G. E., Gebhart, G., Guiot, T., Vanderlinden, B., Larsimont, D., Doumont, G., Van Simaeys, G., Goldman, S., & Flamen, P. (2017). N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89Zr-Trastuzumab and 18F-FDG PET imaging. Oncotarget, 8(34), 56185-56198. doi:10.18632/oncotarget.17015
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Suivant >>